Kenneth Bender, PharmD, MA

With the physician deficit projected to grow larger within a decade, this global challenge has become a major focus of large organizations and medical societies.

With new formulations of effective seizure rescue medications available, epilepsy specialists have begun to refine the approach and education to treating these emergency situations.

Acute encephalopathy, coma, and stroke were among clinically diagnosed neurological symptoms that increased mortality risk in patients with COVID-19.

Advances in MRI and MRS techniques and protocols enhance diagnosis of neuromuscular disorders and provide prognostic and intervention efficacy biomarkers.

Scholz was recognized for her application of advanced genetic techniques to the study of neurodegenerative disorders, including dementia with Lewy bodies, multiple system atrophy, frontotemporal dementia, progressive supranuclear palsy, and corticobasal degeneration.

Efforts to cut through regulatory red tape will help ensure earlier access to potentially lifesaving treatments.

New drug classes and formulations may help hold off breakthrough activity as the research community works to optimize levodopa delivery and absorption.

The Healey ALS Platform Trial learns from successful cancer drug studies to identify and accelerate new treatments for the devastating disease.

Targeting research in cognitive impairment in epilepsy primarily on seizures themselves suggests that a patient’s comorbid problems will resolve with seizure control, though that is not always the case.

The neurological symptoms of migraine aura are generally attributed to cortical spreading depression/depolarization, although that hypothesis does have its detractors. The question of whether CSD triggers migraine headache remains controversial.

An immune profile in blood drawn 2 days after an ischemic stroke has been shown to predict the likelihood of the loss of mental acuity, 1 year later.

The new funding initiatives and innovative programs to expedite research efforts could hasten the search for biomarkers of Alzheimer disease in the blood and, ultimately, open the door to easier, quicker, and more affordable diagnostic methods.

Zonisamide improved Parkinsonism as an adjunct to levodopa in patients with dementia with Lewy bodies in phase 3 trial.

Customizing injection sites and amounts of botulinum toxin for different presentations of essential hand tremor has been shown to avoid hand weakness.

A phase 2 trial demonstrating a PDE-10A inhibitor to be safe but not efficacious for Huntington disease could be followed with the testing of a higher dose.

Botulinum toxin was found to improve restless leg syndrome in the largest, well-controlled study of the investigational intervention to date.

New brain stimulation technology is proven effective for Parkinson in the first double-blind, sham-controlled trial of this type of intervention.

Physicians offer perspectives on newly approved products to prevent migraine.